Iridex Corp (IRIX) Dividend History

Iridex Corporation (IRIX) is a medical device company specializing in ophthalmic surgical and laser therapy systems. Founded in 1984, the company develops innovative laser products for the treatment of ocular diseases, primarily focusing on minimally invasive procedures for conditions such as glaucoma, retinal therapy, and diabetic retinopathy. Iridex's products are used by ophthalmologists worldwide to improve patient outcomes through precise and effective laser treatments.

1212 Terra Bella Ave, Mountain View, CA, 94043
Phone: (650) 940-4700
Website: https://www.iridex.com

Dividend History

Iridex Corp currently does not pay dividends

Company News

  • Iridex Comments on Recent Stock Price Volatility

    Iridex Corporation, a leader in laser-based medical systems for ophthalmology, commented on recent stock price volatility, stating that there have been no material changes to its operating or financial condition.

    GlobeNewswire Inc.
  • Iridex (IRIX) Reports Q1 Loss, Misses Revenue Estimates

    Iridex (IRIX) delivered earnings and revenue surprises of -75% and 1.99%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

    Zacks Investment Research
  • Dow Gains Over 100 Points; Fed Leaves Interest Rates Unchanged

    U.S. stocks traded higher toward the end of trading, after the Federal Reserve announced its policy decision. The Dow traded up 0.40% to 33,185.41 while the NASDAQ rose 0.92% to 12,969.54. The S&P 500 also rose, gaining, 0.67% to 4,221.94. Check This Out: $2.8M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying   Leading and Lagging Sectors Information technology shares jumped by 1.2% on Wednesday. In trading on Wednesday, materials shares fell by 0.6%.   Top Headline The Federal Reserve opted to maintain interest rates at the range of 5.25% to 5.5% during its November meeting, as widely anticipated by the market.   Equities Trading UP Cellectis S.A. (NASDAQ: CLLS) shares shot up 194% to $2.8335. Cellectis reported strategic collaboration and investment agreements with AstraZeneca. Cellectis also presented pre-clinical data on multi-armored allogeneic MUC1-CAR T-cells targeting triple-negative breast cancer at the Society for Immunotherapy of Cancer 38th Annual Meeting. Shares of Patriot Transportation Holding, Inc. (NASDAQ: PATI) got a boost, shooting 103% to $15.59. Patriot Transportation announced an agreement under which United Petroleum Transports will acquire all of the outstanding shares of Patriot common stock for $16.26 per share in cash. TG Therapeutics, Inc. (NASDAQ: TGTX) shares were also up, gaining 32% to $10.18 following ...

    Benzinga
    Featured Companies: PAYC TGTX
Page data last updated 07/24/2025 02:57:23 UTC